肾素—血管紧张素系统与高血压心脏重塑的研究
摘要
高血压是最常见的心血管病，是全球范围内的重大公共卫生问题。长期高血压所造成的心肌左室肥厚(LVH)是心脏事件的独立危险因素。本研究的主要目的是通过观察抗高血压药物，特别是影响肾素-血管紧张素系统(RAS)的ACEI对高血压心肌肥厚的治疗作用，探讨RAS在高血压心脏重塑中的作用。
本研究分为两部分。
第一部分：临床汇总分析
1．研究目的：利用汇总分析(Meta-analysis)的研究方法，观察不同降压药物对高血压伴有左室肥厚患者的逆转作用，尤其对ACEI改善高血压左室肥厚方面是否优于其它药物进行深入探讨。
2．研究方法：
按预先设定的标准，通过互联网和光盘检索，选择国内外所有符合条件的文献数据。
3．统计分析：
将随机对照研究的每一治疗组作为研究对象。计算治疗人数、平均年龄、治疗药物分类、治疗时间、治疗前与治疗后
Hypertension, which is a cardiovascular disease with a high prevelance, remains an greater challenge to the health of the people all over the world. As a consequence of long course of hypertension, cardiac remodeling developed, as well as left ventricular hypertrophy, which is a indedpendent risk factor of cardiac events.
The aim of this study was to investigate the effects of renin angiotensin system (RAS) on the cardiac remodelling in hypertensives. This study consisted of two parts:
1. Clinical meta-analysis on reversal of left ventricular hypertrophy in hypertension
To determine the effects of various antihypertensives agents on the reversal of left ventricular hypertrophy in essential hypertension, particularly the effect of angiotension converting enzyme inhibitor (ACEI) on this field.
1.1. Material and method:
The study material were the literature on which the results of the study of effect of various antihypertensive agents on the reversal of left ventricular hypertrophy in the treatment of
本研究分为两部分。
第一部分：临床汇总分析
1．研究目的：利用汇总分析(Meta-analysis)的研究方法，观察不同降压药物对高血压伴有左室肥厚患者的逆转作用，尤其对ACEI改善高血压左室肥厚方面是否优于其它药物进行深入探讨。
2．研究方法：
按预先设定的标准，通过互联网和光盘检索，选择国内外所有符合条件的文献数据。
3．统计分析：
将随机对照研究的每一治疗组作为研究对象。计算治疗人数、平均年龄、治疗药物分类、治疗时间、治疗前与治疗后
Hypertension, which is a cardiovascular disease with a high prevelance, remains an greater challenge to the health of the people all over the world. As a consequence of long course of hypertension, cardiac remodeling developed, as well as left ventricular hypertrophy, which is a indedpendent risk factor of cardiac events.
The aim of this study was to investigate the effects of renin angiotensin system (RAS) on the cardiac remodelling in hypertensives. This study consisted of two parts:
1. Clinical meta-analysis on reversal of left ventricular hypertrophy in hypertension
To determine the effects of various antihypertensives agents on the reversal of left ventricular hypertrophy in essential hypertension, particularly the effect of angiotension converting enzyme inhibitor (ACEI) on this field.
1.1. Material and method:
The study material were the literature on which the results of the study of effect of various antihypertensive agents on the reversal of left ventricular hypertrophy in the treatment of
引文
1. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997;315:1533-1537
2. Egger M, Smith GD. Meta-analysis: potentials and promise. BMJ. 1997;315:1371-1374
3. Schulz KF, Chalmers I, Hayes PJ, et al. Enopizical evidence of basic dimentions of methodological quality associated with estimates of treatment effects is controlled trials. JAMA. 1995;273:408-412
4．陈鲁原．林曙光．吲哒帕胺和尼群地平对高血压病患者左室肥厚及功能影响的对比性研究 中国临床药理学杂志 1994；10(4)：211-214
5．程学萱，仲肇舒，周一明．卡托普利和尼群地平对老年高血压性左室肥厚影响的对比分析 实用老年医学 1994；8(4)：163-165
6．徐莉芳，周绍甫，于志强，等．硝苯地平与卡托普利对高血压病人左室肥厚的逆转作用比较 沈阳部队医药 1994；7(3)：217-218
7．于金德．卡托普利和吲哒帕胺对高血压病患者左室肥厚和舒张功能影响的对比研究 临床心血管病杂志 1993；(1)：6-9
8．王乐信．硝苯吡啶逆转高血压病患者的左心室肥厚 中华内科杂志 1991；(12)：772-773
9．王乐信．不同类型钙拮抗剂对高血压病患者左心室肥厚的逆转作用 中国循环杂志 1991；(5)：351-353
10．戴伦，林甲宜．氨氯地平逆转Ⅱ期高血压患者左心室肥厚26例临床观察 上海医药 1997；(8)：12-14
11．黄琦磊，陈坦，陈小丽．卡托普利和硝苯吡啶对高血压病人左室肥厚和舒张功能影响的对比研究：附60例疗效观察 福建医药杂志 1997；19(3)：4-6
12．汪碧衡，廖文富，孙明．缓释异搏定与尼群地平治疗高血压性左??心室肥厚的疗效比较 中国动脉硬化杂志 1996；4(2)：128-130
13．杨德业，陈曾仪，唐疾飞，等．培哚普利与硝苯吡啶治疗高血压病的对比研究 温州医学院学报 1997；27(4)：210-212
14．周宗梅，夏义年，胡学锋，等．卡托普利、硝苯地平长期应用对高血压．左室肥厚和心律失常的影响 陕西医学杂志 1997；26(10)：606-608
15．黄琦磊，陈坦，陈小丽．卡托普利和硝苯吡啶对高血压病人左室肥厚和舒张功能影响的对比研究：附60例疗效观察 福建医药杂志 1997；19(3)：4-6
16．任绪功，宋执敬，王平，等．培哚普利与卡托普利对高血压左室肥厚及舒张功能影响的对比研究 中华心血管病杂志 1997；25(3)：211
17．汪碧衡，胡观军．依那普利与缓释异搏定对高血压病患者的疗效比较 中国动脉硬化杂志 1997；5(1)：61-63
18．惠永明，靳守华，陈新根，等．高血压病左室重量与血管紧张素Ⅱ、醛固酮的相互关系及培哚普利、美托洛尔对其影响 临床心血管病杂志 1996；12(4)：216-219
19．惠永明，陈新根，戴中美，等．培哚普利及美托洛尔对高血压病左室肥厚及心功能的影响 中华心血管病杂志 1996；24(3)：216-217
20．汤大鸣，洪秀芳，杨坤河，等．依那普利对高血压病患者左心室舒张功能和心肌肥厚的影响 新疆医学院学报 1996；19(1)：17-20
21．谢秀梅，孙明，周宏研，等．尼群地平与心痛定对老年高血压病左室肥厚的影响 湖南医学 1995；12(6)：323-324
22．徐莉芳，周绍甫，于志强，等．硝苯地平与卡托普利对高血压左室肥厚的逆转作用比较 人民军医 1995；(7)：21-23
23．李小鹰，范利，王新明，等．培哚普利、卡托普利和硝苯地平对高血压左心室肥厚及心功能影响 高血压杂志 1998；6(3)：186-189
24．姜志安，张晓光，郄素芳，等．氯沙坦与氨氯地平治疗高血压病左室肥厚的临床对比研究 河北医科大学学报 1999；20(4)：209-??211
25．胡光，胡长龙．非洛地平与赖诺普利的降压效应及对左室肥厚逆转作用的对比 临床心血管病杂志 1999；15(6)：250-253
26．李小鹰，史扬，曾青云，等．血管紧张素转换酶抑制剂对老年高血压左室肥厚患者心率变异性的影响 中华心律失常学杂志 1998；2(4)：267-269
27. Cheung BM, Lau CP. Fosinopril reduces left ventricular mass in untreated hypertensive patients: a controlled trial. Br J Clin Pharmacol 1999;47:179-87
28. Thurmann PA. Angiotensin Ⅱ antagonism and the heart: valsartan in left ventricular hypertrophy. J Cardiovase Pharmacol 1999;33:33-6
29. Gaudio C, Tanzilli G, Ferri FM, et al. Benazepril causes in hypertension a greater reduction in left ventricular mass than does nitrendipine: a randomized study using magnetic resonance imaging. J Cardiovasc Pharmacol 1998;32:760-8
30. Roman MJ, Alderman MH, Pickering TG,et al. Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy. Am J Hypertens 1998;11:387-96
31. Papademetriou V, Gottdiener JS, Narayan P,et al. Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group. J Am Coll Cardiol 1997;30:1802-8
32. Ueno H, Takata M, Tomita S,et al. The effects of long-term treatment on left ventricular hypertrophy in patients with essential hypertension: relation to changes in neurohumoral factors. J Cardiovasc Pharmacol 1997;30:643-8
33. Schmieder RE, Langenfeld MR, Gatzka Cd,et al. Impact of alphaversus beta-blockers on hypertensive target organ damage: results of a double-blind, randomized, controlled clinical trial. Am J Hypertens??1997; 10:985-91
34. Cheung B. Increased left-ventricular mass after losartan treatment. Lancet 1997;349:1743-4
35. Gottdiener JS, Reda DJ, Massie BM,et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997;95:2007-14
36. Sumimoto T, Ochi T, Ito T,et al. Both a calcium antagonist and ACE inhibitor reverse hypertrophy in hypertension but a calcium antagonist also depresses contractility. Cardiovasc Drugs Ther 1997; 11:27-32
37. Schobel HP, Langenfeld M, Gatzka C,et al. Treatment and posttreatment effects of alpha- versus beta-receptor blockers on left ventricular structure and function in essential hypertension. Am Heart J 1996; 132:1004-9
38. Van Leeuwen JT, Smit AJ, May JF,et al. Comparative effects of diltiazem and lisinopril on left ventricular structure and filling in mild-to-moderate hypertension. J Cardiovasc Pharmacol 1995;26:983-9
39. Agabiti-Rosei E, Ambrosioni E, Dal Palu C,et al. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J Hypertens 1995; 13.1325-34
40. Grandi AM, Bignotti M, Gaudio G,et al. Ambulatory blood pressure and left ventricular changes during antihypertensive treatment: perindopril versus isradipine. J Cardiovasc Pharmacol 1995;26:737-41
41. Hui Y, Dai Z, Chen X,et al. Effect of perindopril and metoprolol on??left ventricular hypertrophy and performance in essential hypertension. Chin Med J (Engl) 1995; 108:678-81
42. Fogari R, Zoppi A, Mugellini A,et al. Effects of lisinopril vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension. Eur Heart J 1995;16:1120-5
43. Vyssoulis GP, Valiouli MA, Karpanou EA,et al. Left ventricular and aortic root structure and function changes with betablocker antihypertensive therapy. A one-year double blind study of celiprolol and metoprolol. Int J Cardiol 1995;49:45-54
44. Kohno M, Horio T, Yokokawa K,et al. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor. Am J Med 1995;98:257-65
45. Liebon PR. Clinical Studies of Drug Reversal of Hypertensive Left Ventricular Hypertrophy. Am J Hypertension. 1990;3:512-517
46. Messerli FH, Aristeizabel D, Soria F.: Reduction of Left Ventricular Hypertrophy is how beneficial? Am Heart J. 1993; 125:1520
47. Dohlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens. 1992;5:85-l 10
48. Schimieder RE, Martus P, Klingbeil A. Peversal of Left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA. 1996;275:1507-1513
49. Dortal DE, Baker KM, Angiotension II stimulation of left ventricular hypertrophy in adult rat heart. Mediation by the AT1 Receptor. Am J Hypertension. 1992;5:276-289
50. de Lannoy LM, Schalekamp MA, Saxena PR, et al. Localization and production of angiotensin II in the isolated perfused rat heart. Hypertension, 1998, 31:1111-1117.51. Lindpainter K, Niedermaier N, Drexler H, et al. Left ventricular remodelling after myocardial infarction. J Cardiovasc Pharmacol, 1992, 20(Suppl 1): S41-47.
52. Liebson PR, Grandis GA, Dianzumba S, et al. Comparason of Five Antihypertensive Monotheropupies and Placebo for Change in Left Ventricular Mass in Patients Receiving Nutritional - Hygienic Therapy in the Treatment of Micel Hypertension Study (TOMHS). Circulation 1995;91:698-706
53. Carey PA, Sheridan DJ. Cordoue A, et al. Effect of indapamide on left ventricular hypertrophy in hypertension. A meta-analysis. Am J Cardiol. 1996; 77:17B-19B.1．李辉，李俭春，江时森。卡托普利对自发性高血压大鼠血压和心肌血管组织AT Ⅱ，E T，NE和DA的影响。中国病理生理杂志 1995；11：308-310。
2. Weber KT, Janicki JS, Shroff SG, et al. Collagen remodelling of the pressure overloaded hypertrophied non-human myocardium. Circ Res. 1988; 62:757-765
3. Brilla CG, Pick R, Tan LB, et al. Remodelling of the rat right and left ventricles in experimental hypertension. Circ Res. 990; 67:1355-64.
4. Weber KT, Anversa P, Armstrong PW, et al. Remodelling and reparation of the cardiovascular system. J Am Col Card. 1992; 20: 3-16.
5. Boluyt MD, O'Neill L, Meredith AL, et al. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure.: marked upregulation of genes encoding extracellular matrix components. Circ Res. 1994; 75:23-32.
6. Dzau VJ. Tissue angiotensin system in cadiovascular medicine: a paradigm shift? Circulation. 1994; 89: 493-498.
7. Weber KT, Sun Y, Schlkens BA, et al. Structural remodelling in hypertensive heat disease and role of hormones. Hypertension. 1994; 23:869-877.
8. Regan CP, Anderson PG, Bishop SP, et al. Captopril prevents vascular and fibrotic changes but not cardiac hypertrophy in aortic-banded rats. Am J Physiol. 1996: 271; H906-H913.
9. Schunkert H, Jackson B, Tang SS, et al. Distribution and functional significance of cardiac angiotensin coverting enzyme in hypertrophied rat??hearts. Circulation. 1993; 87:1328-1339.
10.Matsubara BB, Matsubara LS, Franco M, et al. The effect of nonantihyertensive doses of angiotensin converting enzyme inhibitor on myocardial necrosis and hypertrophy in young rats with renovascular hypertension. Int. J Exp. Path. 1999; 80:97-104.
11.Conrad CH, Brooks WW, Hayes JA, et al. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the SHR. Circulation. 1995; 91:161-170.
12.Kang PM, Landu AJ, Eberhardt RT, et al. Angiotensin II receptor antagonists: a new approach to blocade of the renin-angiotensin system. Am Heart J. 1994; 127: 1388-1401.
13.Goodfriend TL, Elliott ME, Catt KJ. Drug therapy: angiotensin receptos and their antagonists. N Engl J Med. 1996; 334:1649-1654.
14.Brown L, Passmore M, Duce B, et al. Angiotensin receptors in cardiac and renal hypertrophy in rats.
15.Brilla CG, Matsubara L, Weber KT. Advanced hypertensive heart disease in spontanesously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension, 1996; 28: 269-275.
16.Campbell DJ, Kaldis A, Duncan AM. Bradykinin peptieds in kidney, blood and other tissues of rat. Hypertension. 1993; 21:155-65
17.Campbell DJ, Kaladis A, Duncan AM. Effects of angiotensin converting enzyme inhibitor on angitotesin and bradykinin peptides. Hypertension. 1994;23: 439-449.
18.Zhu YC, Stauss HM, Bao G, Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors.19.Nolly H, Miatello R, Damiani MT, et al. Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues. Immunopharmacology. 1997:36; 185-191.
20.Liu YH, Yang XP, Sharov VG, et al. Effects of angiotesin converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin type 2 receptors. J Clin Invest. 1997,99:1926-1935.
21.Wang ZQ, Moore AF, Ozono R, et al. Immunolocalization of subtype 2 angiotensin II receptor protein in rat heart. Hypertension. 1998; 32:78-83.
22.Linz W, Gohlke P; Unger T, et al. Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction. Arch Mal Coeur Vaiss. 1995; 88: 31-34
23.Hu K, Gaudron P, Anders HJ, et al. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1 recepor subtype blokade in rats with myocardial infarction: role of bradykinin. Cardiovasc Res 1998; 39: 401-412.
24.Linz W,Scholkens BA. A specific B2 bradykinin receptor antagonist Hoe 140 abolishes the antihpertrophic effects of ramipril. Br J Pharmacol. 1992 105:771-772.
25.Eleftheriades EG, Durand JB, Ferguson AG, et al. Regulation of procollagen metabolism in the pressure-overloaded rat heart. J Clin Invest. 1993; 91:1113-22.
26.Linz W. Schaper J, Wiemer G, et al. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br J Pharmacol. 1992; 107:970-975.27.Linz W, Wiemer G, Scholkens BA. Contribution of bradykinin to the cardiovascular effects of ramipril. J Cardiovasc Pharmarcol. 1993; 22 (suppl 9):S1-S8.
28.Scholkens BA. Kinins in the cardiovascular system. Immunopharmacology. 1996 33:209-216.
29.Gallagher AM, Yu Hisahiro, Printz MP. Bradykinin-induced reductions in collagen gene expression involve prostacyclin. Hypertension. 1998;32: 84- 88.
30.Wollert KC, Drexler H. The kallikrein-kinin system in post-myocardial infarction cardiac remodelling. Am J Cardiol. 1997: 80: 158A-161A.
31.Kenneth EB. The role of tissue angiotensin converting enzyme: Study of ACE mutant mice. Am J Cardiol. 1998; 82: 5S-7S.
32.Berkenboom G. Bradykinin and the therapeutic actions of angiotensin converting enzyme inhibitors. Am J Cardiol. 1998; 82: 11S-13S.
33.Gibbons GH. Vasculoprotective and cardioprotective mechanism of angiotensin converting enzyme inhibition: the homostatic balance between angiotensin and nitic oxide. Clin Cardiol. 1997; 20:1118-25.
34.Brilla CG, Scheer C, Rupp H. Renin angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblastic function by angiotensin II type 1 receptor antagnism.1. Ferrario CM,Brosnihan KB,Diz DI,et al.Anginotensin-(1-7):A New Hormone of the angiotensin system. Hypertension,1991,18(Suppl Ⅲ):Ⅲ-126-Ⅲ-133
2. Santos RAS,Silva ACS,Magaldi AJ,et al.Evidence for a physiological role of angiontensin-(1-7) in the control of hydroelectrolyte balance. Hypentersion, 1996,27:875-884
3. Ferrario CM,Barnes KL,Block CH,et al. Pathway of angiotensin formation and function in the brain. Hypertension,1990,15(Suppl Ⅰ):Ⅰ-13-Ⅰ-19
4. Jaiswal N,Diz DI,Tallant EQ,et al.Characterization of??angiotensin receptors mediating prostaglandin synthesis in C6 glioma cells. Am J Physiol, 1991,260:R1000-R1006
5. Seyedi N,Xu X,Nasiletti A,et al. Coronary kinin generation mediates nitric oxide release after angiotension receptor stimulation. Hypertension, 1995,26:164-170
6. Felix D,Khosia MC, Zmbodem H,et al. Neurophysiological response to angiotensin- (1-7). Hypentension,1991,17:1111- 1114
7. Welches WR,Santos RAS,Chappell MC,et al.Prolyl endopeptidase participates in the processing of brain angiotensin. J Hypertension, 1991,9:631-63 8
8. Santos RAS,Brosnihan KB,Chappell MC,et al.Converting enzyme activity and angiotensin metabolism in the dog brain stem. Hypertension, 1988,11(Suppl I):I-153-I-157
9. Kohara K,Brosnihan KB,Chappel MC,et al.Angiotensin-(1- 7): A member of circulation angiotensio peptides. Hypertension, 1991,17:131-138
10. Lawrence AC,Evin G,kladis A,et al.An alternative strategy for the radioimmunossay of angiotensin peptides using aminoterminal-directed antisera:Measurement of eight angiotensin peptides in human. J Hypertension, 1990,8:715-724
11. Santos RAS,Brosnihan B,Jacobsen DW,et al.Production of angiotensin-(1-7) by human vascular endothelium. Hypertension, 1992; 19(Suppl II): II -56- II -61
12. Tallant EA,Lu XW,Chappell MC,et al.Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. Hypertension,1997,29(part):388-393
13. Yamamoto K, Chappel MC,Brosniham KB,et al. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertension rats. Hypertension,??1992,19:692-696
14. Chappel MC,Tallant EA,Brosnihan KB,et al.Conversion of angiotensin I to angiotensin-(1-7) by thimet oligopeptidase (EC3.4.25.15) in vascular smooth muscle cells. J Vase Biol Med,1995,5:129-137
15. Koida M, Walter R. Post-proline cleaving enzyme.J Biol Chem. 1976;251:7593-7599
16. Kumamoto k, Stewart TA, Johnson AR et al. Prolylcarboxypeptidase (angiotensinase C) in human lung and cultured cells.J Clin Invest. 1981;67:210-215.
17. Ferraio CM, Chappell MC, Tallant EA et al. Counterregulatory action of Angtiotensin-(1-7). Hypertension. 1997;30[part2]:535-541
18 Luque M,Martin P,Martell N,et al. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertension, 1996,14:799—805.
18. Santos RAS, Brosnihan KB. Jacobsen DW et al. Production of Angiotensin-(1-7) by human Vascularendothelium. Hypertension. 1992;19[suppl Ⅱ] Ⅱ-56-Ⅱ-61.
19. Ferriario CM, Briosnihan KB, Diz DI et al. Angiotensin-(1-7): A new hormone of the angiotensin system.Hypertension 1991;18[suppl Ⅲ]Ⅲ-126-Ⅲ-133.
20. Yamamoto K, Chappell MC, Brosinhan KB, et al. In vivo metabolism of angiotensinI by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension. 1992;19;692-696
21. Chappel MC,Brosinhan KB, Diz DI et al. Identification of Angiotensin-(1-7) in rat brain.J Biol Chem.1989;264(28): 16518-16523
22. Roks AJ, van Geel PP, Pinto YM, et al. Angiotensin-(1-7) is a??modulator of the human renin-angiotensin system. Hypertension 1999;34(2):296-301.
23. Schiavone MT,Santos RAS,Brosnihan KB,et al.Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci USA,1988,85:4095-4098
24. Campagnole-Santos MJ,Diz DI,Santos RAS,et al.Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of ratsc. Am J Physiol, 1989,257: H324-H329
25. Jaiswal N,Tallant EA,Diz Dl,et al. Subtype 2 angiotensin receptors mediate prostaglandin synthesis in human astrocytes. Hypertension, 1991,17:1115-1120
26. Jaisawal N,diz DI,Chappell MC,et al.Stimulation of endothelial cell prostaglandin production by angiotensin peptides: Characterization of receptors. Hypertension, 1992,19(Suppl II): II-49-II-55
27. Jaiswal N,Tallant EA,Jaiswal RK,et al.Differential regulation of prostaglandin synthesis by angiotension peptides in porcine aortic smooth muscle cells:subtypes of angiotension receptors involved. J Pharmacol Exp Ther,1993,265:664-673
28. Benter IF, Diz DI, Ferrario CM. Cardiovascular actions of angiotensin-(1 -7).Peptides, 1993,14:679-684
29. Meng W,Busija DW.Comparative effects of angiotensin-(1-7) and angiotensin II on piglet pial arterioles. Stroke, 1993,24:2041 -2045
30. Tallant EA,Jaiswal NJ,Diz DI,et al.Human astrocytes contain two distinct angiotensin receptor subtypes. Hypertension, 1991,18:32-39
31. Porsti I,Bara AT,Busse R,et al.Release of nitrio oxide by angiotensin-(1-7) from porcine coronary??endothelium:implications for a novel angiotensin receptor. Br J Pharmacol, 1994,111:652-654
32. Brosnihan KB,Li P,Ferrario CM.Angiotensin-(1-7)dilates canine coronary arteries through kinins and nitric oxide. Hypertension, 1996,27:523-528
33. Osei SY,Ahima RS,Minkes PK,et al.Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular bedsc. Eur J Pharmacol,1993,234:35-42
34. Li Ping, Chappell MC, Ferrario CM, et al.angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension, 1997, 29 (part2): 394-400
35. Brosinihan KB, Li P, Ferrario CM, et al. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension .1996;27:523-528.
36. Paula RD, Lima CV, Khosla MC, et al. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats Hypertension 1995;26[part2]:1154-1159.
37. Lima CV, Paula RD, Resende FL, et al. Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats. Hypertension 1997;30[part2]:542-548.
38. Abbas A, Gorelik G, Carbini LA, et al. Angiotensin-(1-7) induces bradykinin-mediated hypotensive responses in anestletized rats. Hypertension 1997;30[part1]:217-221
39. Paula RD, Lima CV, Britto RR, et al. Potentiation of hypotensive effect of bradykinin by angiotensin-(1-7)-related peptides. Peptides 1999;20(4):493-500.
40. LiP,Chappell MC, Ferrario CM, et al. Angiotensin- (1-7) auguments bradykinin-induced vasodilation by competing with??ACE and releasing nitric oxide. Hypertension. 1997;29 [part2]; 394-400
41. Tallant EA, Lu XW, BVeiss RB, et al. Bovine Aortic endothelial cells contain an angiotensin-(1-7) receptor.Hypertension. 1997;29[part2]:388-393.
42. Davie AP, McMurray JJ. Effect of angiotension-(1-7) and bradykinin in patients with heart failure treated with an ACE inhibitor. Hypertension 1999;34(3):457-460.
43. Benter IF,Ferrario CM,Morris M,et al.Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive ratsc. Am J Pyhsiol, 1995,269:H313-H319
44. Garcia NII,Garvin JI.Angiotensin-(1-7) has a biphasic effect on fluid absorption in the proximal straight tubule. J Am SOC Nephrol,1994,5:1133-1138
45. Meng W, Busija DW. Comparative effects of angiotensin-(1-7) and angiotensin II on piglet pial arterioles Stroke 1993 ;24:2041-2045.
46. Freeman EJ,Ferrario CM,Tallant EA,et al. Angiotensins differentially activate phopholiphase D in vascular smooth muscle cells from spontaneously hypertensive and Wistar-Kyoto rats. Am J Hypertension, 1995,8:1105-1111
47. Freeman EJ,Chisolm GM,Ferrario CM,et al. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension, 1996,28:104-108
48. Tsllant EA, Diz DI, Ferrario CM. Antiproliferative actions of angiotension-(1-7) in vascular smooth muscle. Hypertension 1999;34(4 part 2):950-957.
49. Tallant EA,Diz DI,khosla MC,et al.ldentification and regulation of angiotensin II receptor subtypes on NG108-15 cells. Hypertension, 1991,17:1135-114450. Deddish PA, Marcis B, Jackman HC, et al.N-domain-specific substrate and c-domain inhibitors of angiotensin-covertingenzyme angiotensin-(1-7) and keto-ACE. Hypertension, 1998,31:912-917
51. Minshall RD,Tan F,Nakamura F,et al.Potentiation of the actions of bradykinin by angiotensinlcoverting enzyme(ACE) inbitors:the role of expressed and ACE in CHO cells. Circ Res,1997,81:848-856
52. Minshall RD,Erdos EG,Vogel SM.Angiotensinl coverting enzyme inhibitors potentiate brdykinin's inortropic effects independentlly of blocking its inactivation. Am J Cardiol,1997,80:132-136
53. Iyber SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension. 1998;31 [part2]:356- 361
54. Zyer SN, Chappel MC, Avevill DB, et al. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension. 1998;31:699-705.
55. Kohara K, Brosnihan KB, Ferrario CM, Angiotensin-(1-7) in spontaneously hypertensive rat. Peptides.1993;14:883-891
56. Chappell MC, Pirro NT, Sykes A. et al. Metabolism of angiotensin-(1-7) by angiotensin-coverting enzyme .Hypertension. 1998;31[part2]:362-367.
57. Tallant EA, Ferrario CM. Biology of angiotensin II receptor inhabition with a focus on losartan.a new drug for treatment of hypertension. Exp Opin Invest Drugs 1996;5:1201-1214
58. Ferrario CM, Martell N,Pinillas C,et al.Essential hypertension in associated with low urinary levels of angiotensin-(1-7).??Hypertension, 1996,28:515
59. Chappell MC,Diz DI,Ferrario CM.Urinary angiotensin-(1- 7):influence of converting enzyme and neprilysin inhibition. Hypertension, 1995,26:542
60. Ferrario CM, Chappell MC, Tallant EA, et al. Counterregulatory Actions of angiotensin-(1-7). Hypertension, 1997;30(part 2):535-5411 Swedberg K, Held P, Kjekshus J, et al. Effects of the earl administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study Ⅱ (CONSENSUS Ⅱ). N Engl J Med, 1992, 327: 678-684.
2 Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet, 1994, 343: 1115-1122.
3 ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet, 1995, 345: 669-685.
4 Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction (CCS-1). Lancet, 1995, 345: 686-687.
5 Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventrieular enlargement trial. N Engl J Med, 1992, 327:??669-677.
6 Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. N Engl J Med, 1995, 332: 80-85.
7 The Acute Infarction Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet, 1993, 342:821-828.
8 Hall AS, Murray GD, Ball SG. Follow up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet, 1997, 349:1493- 1497.
9 ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Circulation, 1998, 97:2202-2212.
10 MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease, part I: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet, 1990, 335: 765-774.
11 Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensinconverting enzyme inhibitors in cardiac and vascular protection. Circulation, 1994, 90:2056-2069.
12 Iwai N, Kinoshita, Ohmichi N, et al. Renin is expressed in rat macrophage/monocyte cells. Hypertension, 1996, 27(3 Pt 1): 399-403.
13 Danser AHJ, van Kesteren CAM, Bax WA, et al.??Prorenin,renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation, 1997, 96:220-226.
14 de Lannoy LM, Schalekamp MA, Saxena PR, et al. Localization and production of angiotensin II in the isolated perfused rat heart. Hypertension, 1998, 31:1111-1117.
15 Lindpainter K, Niedermaier N, Drexler H, et al. Left ventricular remodelling after myocardial infarction. J Cardiovasc Pharmacol, 1992, 20 (Suppl 1): S41-47.
16 Zhuo JL, Froomes P, Casley D, et al. Perindopril chronically inhibits angiotensin converting enzyme in both the endothelium and adventitial of the internal mammay artery in patients with ischemic heart disease. Circulation. 1997, 96: 174-182.
17 Hilgers KF, Veelken R, Schmieder RE, et al. Angiotensinases restrict locally generated angiotensin II to the blood vessel wall. Hypertension. 1998, 31(1 Pt 2): 368-372.
18 Naftilin AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest. 1989, 83:1419-1474.
19 Naftilin AJ, Pratt RE,Eldbridge CS, et al. Angiotensin II induces c-fos expression in smooth muscle cell via transcriptional control. Hypertension; 1989, 13: 706-711.
20 Morishita R, Gibbons GH, Dllison KE, et al. Evidence for direct local effect of angiotensin in vascular hypertrophy: in vivo gene transfer of angiotensin converting enzyme. J Clin Invest. 1994, 94: 978-984.
21 Isner JM, Kearney M, Bortman S,et al.Apoptosis in human atherosclerosis and restenosis. Circulation. 1995, 91: 2703- 2711.22 Gohlke P, Lamberty V, Kuwer I, et al. Long-term low-dose angiotensin converting enzyme inhibitor treatment increases vascular cyclic guanosine 3',5'--monophosphate. Hypertension. 1993, 22:682-687.
23 Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 1997, 95: 1115-1118.
24 Gallagher AM, Yu H, Printz MR Bradykinin-induced reduction in collagen gene expression involve prostacyclin. Hypertension, 1998, 32:84-88.
25 Huang W, Gelas FA, Osborne-Pellegrin MJ. Protection of the arterial internal elastic lamina by inhibition of the reninangiotensin system in the rat. Circ Res, 1998, 82: 879-890.
26 Mancini GB, Henry GC, Macaya C, et al. Angiotensinconverting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfuction) Study.Circulation, 1996, 94: 258-265.
27 Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide antiotensin IV. J Clin Invest, 1995, 96: 2515-2520.
28 Vaughan DE, Pfeffer MA, Menapace FJ, et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation, 1997, 96: 442-447.
29 Gibbons GH. Vasculoprotective and cardioprotective mechanism of angiotensin-converting enzyme inhibition: the homeostatic balanc between angiotensin II and nitric oxide. Clin Cardiol, 1997, 20(Suppl II) 1118-1125.
30 Hu K, Gaudron P, Anders HJ, et al. Chronic effects of early??started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin. Cardiovasc Res, 1998, 39: 401-412.
31 Makino N, Sugano M, Hata T, et al. Chronic low-dose treatment with enalapril induced cardiac regression of left ventricular hypertrophy. Mol Cell Biochem, 1996, 163-164.
32 Urata H, Ganten D, Dishiumura H. Chymase-dependent angiotensin Ⅱ forming system in humans. Am J Hypertens, 1996, 9: 277-84.
2. Egger M, Smith GD. Meta-analysis: potentials and promise. BMJ. 1997;315:1371-1374
3. Schulz KF, Chalmers I, Hayes PJ, et al. Enopizical evidence of basic dimentions of methodological quality associated with estimates of treatment effects is controlled trials. JAMA. 1995;273:408-412
4．陈鲁原．林曙光．吲哒帕胺和尼群地平对高血压病患者左室肥厚及功能影响的对比性研究 中国临床药理学杂志 1994；10(4)：211-214
5．程学萱，仲肇舒，周一明．卡托普利和尼群地平对老年高血压性左室肥厚影响的对比分析 实用老年医学 1994；8(4)：163-165
6．徐莉芳，周绍甫，于志强，等．硝苯地平与卡托普利对高血压病人左室肥厚的逆转作用比较 沈阳部队医药 1994；7(3)：217-218
7．于金德．卡托普利和吲哒帕胺对高血压病患者左室肥厚和舒张功能影响的对比研究 临床心血管病杂志 1993；(1)：6-9
8．王乐信．硝苯吡啶逆转高血压病患者的左心室肥厚 中华内科杂志 1991；(12)：772-773
9．王乐信．不同类型钙拮抗剂对高血压病患者左心室肥厚的逆转作用 中国循环杂志 1991；(5)：351-353
10．戴伦，林甲宜．氨氯地平逆转Ⅱ期高血压患者左心室肥厚26例临床观察 上海医药 1997；(8)：12-14
11．黄琦磊，陈坦，陈小丽．卡托普利和硝苯吡啶对高血压病人左室肥厚和舒张功能影响的对比研究：附60例疗效观察 福建医药杂志 1997；19(3)：4-6
12．汪碧衡，廖文富，孙明．缓释异搏定与尼群地平治疗高血压性左??心室肥厚的疗效比较 中国动脉硬化杂志 1996；4(2)：128-130
13．杨德业，陈曾仪，唐疾飞，等．培哚普利与硝苯吡啶治疗高血压病的对比研究 温州医学院学报 1997；27(4)：210-212
14．周宗梅，夏义年，胡学锋，等．卡托普利、硝苯地平长期应用对高血压．左室肥厚和心律失常的影响 陕西医学杂志 1997；26(10)：606-608
15．黄琦磊，陈坦，陈小丽．卡托普利和硝苯吡啶对高血压病人左室肥厚和舒张功能影响的对比研究：附60例疗效观察 福建医药杂志 1997；19(3)：4-6
16．任绪功，宋执敬，王平，等．培哚普利与卡托普利对高血压左室肥厚及舒张功能影响的对比研究 中华心血管病杂志 1997；25(3)：211
17．汪碧衡，胡观军．依那普利与缓释异搏定对高血压病患者的疗效比较 中国动脉硬化杂志 1997；5(1)：61-63
18．惠永明，靳守华，陈新根，等．高血压病左室重量与血管紧张素Ⅱ、醛固酮的相互关系及培哚普利、美托洛尔对其影响 临床心血管病杂志 1996；12(4)：216-219
19．惠永明，陈新根，戴中美，等．培哚普利及美托洛尔对高血压病左室肥厚及心功能的影响 中华心血管病杂志 1996；24(3)：216-217
20．汤大鸣，洪秀芳，杨坤河，等．依那普利对高血压病患者左心室舒张功能和心肌肥厚的影响 新疆医学院学报 1996；19(1)：17-20
21．谢秀梅，孙明，周宏研，等．尼群地平与心痛定对老年高血压病左室肥厚的影响 湖南医学 1995；12(6)：323-324
22．徐莉芳，周绍甫，于志强，等．硝苯地平与卡托普利对高血压左室肥厚的逆转作用比较 人民军医 1995；(7)：21-23
23．李小鹰，范利，王新明，等．培哚普利、卡托普利和硝苯地平对高血压左心室肥厚及心功能影响 高血压杂志 1998；6(3)：186-189
24．姜志安，张晓光，郄素芳，等．氯沙坦与氨氯地平治疗高血压病左室肥厚的临床对比研究 河北医科大学学报 1999；20(4)：209-??211
25．胡光，胡长龙．非洛地平与赖诺普利的降压效应及对左室肥厚逆转作用的对比 临床心血管病杂志 1999；15(6)：250-253
26．李小鹰，史扬，曾青云，等．血管紧张素转换酶抑制剂对老年高血压左室肥厚患者心率变异性的影响 中华心律失常学杂志 1998；2(4)：267-269
27. Cheung BM, Lau CP. Fosinopril reduces left ventricular mass in untreated hypertensive patients: a controlled trial. Br J Clin Pharmacol 1999;47:179-87
28. Thurmann PA. Angiotensin Ⅱ antagonism and the heart: valsartan in left ventricular hypertrophy. J Cardiovase Pharmacol 1999;33:33-6
29. Gaudio C, Tanzilli G, Ferri FM, et al. Benazepril causes in hypertension a greater reduction in left ventricular mass than does nitrendipine: a randomized study using magnetic resonance imaging. J Cardiovasc Pharmacol 1998;32:760-8
30. Roman MJ, Alderman MH, Pickering TG,et al. Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy. Am J Hypertens 1998;11:387-96
31. Papademetriou V, Gottdiener JS, Narayan P,et al. Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group. J Am Coll Cardiol 1997;30:1802-8
32. Ueno H, Takata M, Tomita S,et al. The effects of long-term treatment on left ventricular hypertrophy in patients with essential hypertension: relation to changes in neurohumoral factors. J Cardiovasc Pharmacol 1997;30:643-8
33. Schmieder RE, Langenfeld MR, Gatzka Cd,et al. Impact of alphaversus beta-blockers on hypertensive target organ damage: results of a double-blind, randomized, controlled clinical trial. Am J Hypertens??1997; 10:985-91
34. Cheung B. Increased left-ventricular mass after losartan treatment. Lancet 1997;349:1743-4
35. Gottdiener JS, Reda DJ, Massie BM,et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997;95:2007-14
36. Sumimoto T, Ochi T, Ito T,et al. Both a calcium antagonist and ACE inhibitor reverse hypertrophy in hypertension but a calcium antagonist also depresses contractility. Cardiovasc Drugs Ther 1997; 11:27-32
37. Schobel HP, Langenfeld M, Gatzka C,et al. Treatment and posttreatment effects of alpha- versus beta-receptor blockers on left ventricular structure and function in essential hypertension. Am Heart J 1996; 132:1004-9
38. Van Leeuwen JT, Smit AJ, May JF,et al. Comparative effects of diltiazem and lisinopril on left ventricular structure and filling in mild-to-moderate hypertension. J Cardiovasc Pharmacol 1995;26:983-9
39. Agabiti-Rosei E, Ambrosioni E, Dal Palu C,et al. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J Hypertens 1995; 13.1325-34
40. Grandi AM, Bignotti M, Gaudio G,et al. Ambulatory blood pressure and left ventricular changes during antihypertensive treatment: perindopril versus isradipine. J Cardiovasc Pharmacol 1995;26:737-41
41. Hui Y, Dai Z, Chen X,et al. Effect of perindopril and metoprolol on??left ventricular hypertrophy and performance in essential hypertension. Chin Med J (Engl) 1995; 108:678-81
42. Fogari R, Zoppi A, Mugellini A,et al. Effects of lisinopril vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension. Eur Heart J 1995;16:1120-5
43. Vyssoulis GP, Valiouli MA, Karpanou EA,et al. Left ventricular and aortic root structure and function changes with betablocker antihypertensive therapy. A one-year double blind study of celiprolol and metoprolol. Int J Cardiol 1995;49:45-54
44. Kohno M, Horio T, Yokokawa K,et al. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor. Am J Med 1995;98:257-65
45. Liebon PR. Clinical Studies of Drug Reversal of Hypertensive Left Ventricular Hypertrophy. Am J Hypertension. 1990;3:512-517
46. Messerli FH, Aristeizabel D, Soria F.: Reduction of Left Ventricular Hypertrophy is how beneficial? Am Heart J. 1993; 125:1520
47. Dohlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens. 1992;5:85-l 10
48. Schimieder RE, Martus P, Klingbeil A. Peversal of Left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA. 1996;275:1507-1513
49. Dortal DE, Baker KM, Angiotension II stimulation of left ventricular hypertrophy in adult rat heart. Mediation by the AT1 Receptor. Am J Hypertension. 1992;5:276-289
50. de Lannoy LM, Schalekamp MA, Saxena PR, et al. Localization and production of angiotensin II in the isolated perfused rat heart. Hypertension, 1998, 31:1111-1117.51. Lindpainter K, Niedermaier N, Drexler H, et al. Left ventricular remodelling after myocardial infarction. J Cardiovasc Pharmacol, 1992, 20(Suppl 1): S41-47.
52. Liebson PR, Grandis GA, Dianzumba S, et al. Comparason of Five Antihypertensive Monotheropupies and Placebo for Change in Left Ventricular Mass in Patients Receiving Nutritional - Hygienic Therapy in the Treatment of Micel Hypertension Study (TOMHS). Circulation 1995;91:698-706
53. Carey PA, Sheridan DJ. Cordoue A, et al. Effect of indapamide on left ventricular hypertrophy in hypertension. A meta-analysis. Am J Cardiol. 1996; 77:17B-19B.1．李辉，李俭春，江时森。卡托普利对自发性高血压大鼠血压和心肌血管组织AT Ⅱ，E T，NE和DA的影响。中国病理生理杂志 1995；11：308-310。
2. Weber KT, Janicki JS, Shroff SG, et al. Collagen remodelling of the pressure overloaded hypertrophied non-human myocardium. Circ Res. 1988; 62:757-765
3. Brilla CG, Pick R, Tan LB, et al. Remodelling of the rat right and left ventricles in experimental hypertension. Circ Res. 990; 67:1355-64.
4. Weber KT, Anversa P, Armstrong PW, et al. Remodelling and reparation of the cardiovascular system. J Am Col Card. 1992; 20: 3-16.
5. Boluyt MD, O'Neill L, Meredith AL, et al. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure.: marked upregulation of genes encoding extracellular matrix components. Circ Res. 1994; 75:23-32.
6. Dzau VJ. Tissue angiotensin system in cadiovascular medicine: a paradigm shift? Circulation. 1994; 89: 493-498.
7. Weber KT, Sun Y, Schlkens BA, et al. Structural remodelling in hypertensive heat disease and role of hormones. Hypertension. 1994; 23:869-877.
8. Regan CP, Anderson PG, Bishop SP, et al. Captopril prevents vascular and fibrotic changes but not cardiac hypertrophy in aortic-banded rats. Am J Physiol. 1996: 271; H906-H913.
9. Schunkert H, Jackson B, Tang SS, et al. Distribution and functional significance of cardiac angiotensin coverting enzyme in hypertrophied rat??hearts. Circulation. 1993; 87:1328-1339.
10.Matsubara BB, Matsubara LS, Franco M, et al. The effect of nonantihyertensive doses of angiotensin converting enzyme inhibitor on myocardial necrosis and hypertrophy in young rats with renovascular hypertension. Int. J Exp. Path. 1999; 80:97-104.
11.Conrad CH, Brooks WW, Hayes JA, et al. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the SHR. Circulation. 1995; 91:161-170.
12.Kang PM, Landu AJ, Eberhardt RT, et al. Angiotensin II receptor antagonists: a new approach to blocade of the renin-angiotensin system. Am Heart J. 1994; 127: 1388-1401.
13.Goodfriend TL, Elliott ME, Catt KJ. Drug therapy: angiotensin receptos and their antagonists. N Engl J Med. 1996; 334:1649-1654.
14.Brown L, Passmore M, Duce B, et al. Angiotensin receptors in cardiac and renal hypertrophy in rats.
15.Brilla CG, Matsubara L, Weber KT. Advanced hypertensive heart disease in spontanesously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension, 1996; 28: 269-275.
16.Campbell DJ, Kaldis A, Duncan AM. Bradykinin peptieds in kidney, blood and other tissues of rat. Hypertension. 1993; 21:155-65
17.Campbell DJ, Kaladis A, Duncan AM. Effects of angiotensin converting enzyme inhibitor on angitotesin and bradykinin peptides. Hypertension. 1994;23: 439-449.
18.Zhu YC, Stauss HM, Bao G, Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors.19.Nolly H, Miatello R, Damiani MT, et al. Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues. Immunopharmacology. 1997:36; 185-191.
20.Liu YH, Yang XP, Sharov VG, et al. Effects of angiotesin converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin type 2 receptors. J Clin Invest. 1997,99:1926-1935.
21.Wang ZQ, Moore AF, Ozono R, et al. Immunolocalization of subtype 2 angiotensin II receptor protein in rat heart. Hypertension. 1998; 32:78-83.
22.Linz W, Gohlke P; Unger T, et al. Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction. Arch Mal Coeur Vaiss. 1995; 88: 31-34
23.Hu K, Gaudron P, Anders HJ, et al. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1 recepor subtype blokade in rats with myocardial infarction: role of bradykinin. Cardiovasc Res 1998; 39: 401-412.
24.Linz W,Scholkens BA. A specific B2 bradykinin receptor antagonist Hoe 140 abolishes the antihpertrophic effects of ramipril. Br J Pharmacol. 1992 105:771-772.
25.Eleftheriades EG, Durand JB, Ferguson AG, et al. Regulation of procollagen metabolism in the pressure-overloaded rat heart. J Clin Invest. 1993; 91:1113-22.
26.Linz W. Schaper J, Wiemer G, et al. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br J Pharmacol. 1992; 107:970-975.27.Linz W, Wiemer G, Scholkens BA. Contribution of bradykinin to the cardiovascular effects of ramipril. J Cardiovasc Pharmarcol. 1993; 22 (suppl 9):S1-S8.
28.Scholkens BA. Kinins in the cardiovascular system. Immunopharmacology. 1996 33:209-216.
29.Gallagher AM, Yu Hisahiro, Printz MP. Bradykinin-induced reductions in collagen gene expression involve prostacyclin. Hypertension. 1998;32: 84- 88.
30.Wollert KC, Drexler H. The kallikrein-kinin system in post-myocardial infarction cardiac remodelling. Am J Cardiol. 1997: 80: 158A-161A.
31.Kenneth EB. The role of tissue angiotensin converting enzyme: Study of ACE mutant mice. Am J Cardiol. 1998; 82: 5S-7S.
32.Berkenboom G. Bradykinin and the therapeutic actions of angiotensin converting enzyme inhibitors. Am J Cardiol. 1998; 82: 11S-13S.
33.Gibbons GH. Vasculoprotective and cardioprotective mechanism of angiotensin converting enzyme inhibition: the homostatic balance between angiotensin and nitic oxide. Clin Cardiol. 1997; 20:1118-25.
34.Brilla CG, Scheer C, Rupp H. Renin angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblastic function by angiotensin II type 1 receptor antagnism.1. Ferrario CM,Brosnihan KB,Diz DI,et al.Anginotensin-(1-7):A New Hormone of the angiotensin system. Hypertension,1991,18(Suppl Ⅲ):Ⅲ-126-Ⅲ-133
2. Santos RAS,Silva ACS,Magaldi AJ,et al.Evidence for a physiological role of angiontensin-(1-7) in the control of hydroelectrolyte balance. Hypentersion, 1996,27:875-884
3. Ferrario CM,Barnes KL,Block CH,et al. Pathway of angiotensin formation and function in the brain. Hypertension,1990,15(Suppl Ⅰ):Ⅰ-13-Ⅰ-19
4. Jaiswal N,Diz DI,Tallant EQ,et al.Characterization of??angiotensin receptors mediating prostaglandin synthesis in C6 glioma cells. Am J Physiol, 1991,260:R1000-R1006
5. Seyedi N,Xu X,Nasiletti A,et al. Coronary kinin generation mediates nitric oxide release after angiotension receptor stimulation. Hypertension, 1995,26:164-170
6. Felix D,Khosia MC, Zmbodem H,et al. Neurophysiological response to angiotensin- (1-7). Hypentension,1991,17:1111- 1114
7. Welches WR,Santos RAS,Chappell MC,et al.Prolyl endopeptidase participates in the processing of brain angiotensin. J Hypertension, 1991,9:631-63 8
8. Santos RAS,Brosnihan KB,Chappell MC,et al.Converting enzyme activity and angiotensin metabolism in the dog brain stem. Hypertension, 1988,11(Suppl I):I-153-I-157
9. Kohara K,Brosnihan KB,Chappel MC,et al.Angiotensin-(1- 7): A member of circulation angiotensio peptides. Hypertension, 1991,17:131-138
10. Lawrence AC,Evin G,kladis A,et al.An alternative strategy for the radioimmunossay of angiotensin peptides using aminoterminal-directed antisera:Measurement of eight angiotensin peptides in human. J Hypertension, 1990,8:715-724
11. Santos RAS,Brosnihan B,Jacobsen DW,et al.Production of angiotensin-(1-7) by human vascular endothelium. Hypertension, 1992; 19(Suppl II): II -56- II -61
12. Tallant EA,Lu XW,Chappell MC,et al.Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. Hypertension,1997,29(part):388-393
13. Yamamoto K, Chappel MC,Brosniham KB,et al. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertension rats. Hypertension,??1992,19:692-696
14. Chappel MC,Tallant EA,Brosnihan KB,et al.Conversion of angiotensin I to angiotensin-(1-7) by thimet oligopeptidase (EC3.4.25.15) in vascular smooth muscle cells. J Vase Biol Med,1995,5:129-137
15. Koida M, Walter R. Post-proline cleaving enzyme.J Biol Chem. 1976;251:7593-7599
16. Kumamoto k, Stewart TA, Johnson AR et al. Prolylcarboxypeptidase (angiotensinase C) in human lung and cultured cells.J Clin Invest. 1981;67:210-215.
17. Ferraio CM, Chappell MC, Tallant EA et al. Counterregulatory action of Angtiotensin-(1-7). Hypertension. 1997;30[part2]:535-541
18 Luque M,Martin P,Martell N,et al. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertension, 1996,14:799—805.
18. Santos RAS, Brosnihan KB. Jacobsen DW et al. Production of Angiotensin-(1-7) by human Vascularendothelium. Hypertension. 1992;19[suppl Ⅱ] Ⅱ-56-Ⅱ-61.
19. Ferriario CM, Briosnihan KB, Diz DI et al. Angiotensin-(1-7): A new hormone of the angiotensin system.Hypertension 1991;18[suppl Ⅲ]Ⅲ-126-Ⅲ-133.
20. Yamamoto K, Chappell MC, Brosinhan KB, et al. In vivo metabolism of angiotensinI by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension. 1992;19;692-696
21. Chappel MC,Brosinhan KB, Diz DI et al. Identification of Angiotensin-(1-7) in rat brain.J Biol Chem.1989;264(28): 16518-16523
22. Roks AJ, van Geel PP, Pinto YM, et al. Angiotensin-(1-7) is a??modulator of the human renin-angiotensin system. Hypertension 1999;34(2):296-301.
23. Schiavone MT,Santos RAS,Brosnihan KB,et al.Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci USA,1988,85:4095-4098
24. Campagnole-Santos MJ,Diz DI,Santos RAS,et al.Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of ratsc. Am J Physiol, 1989,257: H324-H329
25. Jaiswal N,Tallant EA,Diz Dl,et al. Subtype 2 angiotensin receptors mediate prostaglandin synthesis in human astrocytes. Hypertension, 1991,17:1115-1120
26. Jaisawal N,diz DI,Chappell MC,et al.Stimulation of endothelial cell prostaglandin production by angiotensin peptides: Characterization of receptors. Hypertension, 1992,19(Suppl II): II-49-II-55
27. Jaiswal N,Tallant EA,Jaiswal RK,et al.Differential regulation of prostaglandin synthesis by angiotension peptides in porcine aortic smooth muscle cells:subtypes of angiotension receptors involved. J Pharmacol Exp Ther,1993,265:664-673
28. Benter IF, Diz DI, Ferrario CM. Cardiovascular actions of angiotensin-(1 -7).Peptides, 1993,14:679-684
29. Meng W,Busija DW.Comparative effects of angiotensin-(1-7) and angiotensin II on piglet pial arterioles. Stroke, 1993,24:2041 -2045
30. Tallant EA,Jaiswal NJ,Diz DI,et al.Human astrocytes contain two distinct angiotensin receptor subtypes. Hypertension, 1991,18:32-39
31. Porsti I,Bara AT,Busse R,et al.Release of nitrio oxide by angiotensin-(1-7) from porcine coronary??endothelium:implications for a novel angiotensin receptor. Br J Pharmacol, 1994,111:652-654
32. Brosnihan KB,Li P,Ferrario CM.Angiotensin-(1-7)dilates canine coronary arteries through kinins and nitric oxide. Hypertension, 1996,27:523-528
33. Osei SY,Ahima RS,Minkes PK,et al.Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular bedsc. Eur J Pharmacol,1993,234:35-42
34. Li Ping, Chappell MC, Ferrario CM, et al.angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension, 1997, 29 (part2): 394-400
35. Brosinihan KB, Li P, Ferrario CM, et al. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension .1996;27:523-528.
36. Paula RD, Lima CV, Khosla MC, et al. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats Hypertension 1995;26[part2]:1154-1159.
37. Lima CV, Paula RD, Resende FL, et al. Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats. Hypertension 1997;30[part2]:542-548.
38. Abbas A, Gorelik G, Carbini LA, et al. Angiotensin-(1-7) induces bradykinin-mediated hypotensive responses in anestletized rats. Hypertension 1997;30[part1]:217-221
39. Paula RD, Lima CV, Britto RR, et al. Potentiation of hypotensive effect of bradykinin by angiotensin-(1-7)-related peptides. Peptides 1999;20(4):493-500.
40. LiP,Chappell MC, Ferrario CM, et al. Angiotensin- (1-7) auguments bradykinin-induced vasodilation by competing with??ACE and releasing nitric oxide. Hypertension. 1997;29 [part2]; 394-400
41. Tallant EA, Lu XW, BVeiss RB, et al. Bovine Aortic endothelial cells contain an angiotensin-(1-7) receptor.Hypertension. 1997;29[part2]:388-393.
42. Davie AP, McMurray JJ. Effect of angiotension-(1-7) and bradykinin in patients with heart failure treated with an ACE inhibitor. Hypertension 1999;34(3):457-460.
43. Benter IF,Ferrario CM,Morris M,et al.Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive ratsc. Am J Pyhsiol, 1995,269:H313-H319
44. Garcia NII,Garvin JI.Angiotensin-(1-7) has a biphasic effect on fluid absorption in the proximal straight tubule. J Am SOC Nephrol,1994,5:1133-1138
45. Meng W, Busija DW. Comparative effects of angiotensin-(1-7) and angiotensin II on piglet pial arterioles Stroke 1993 ;24:2041-2045.
46. Freeman EJ,Ferrario CM,Tallant EA,et al. Angiotensins differentially activate phopholiphase D in vascular smooth muscle cells from spontaneously hypertensive and Wistar-Kyoto rats. Am J Hypertension, 1995,8:1105-1111
47. Freeman EJ,Chisolm GM,Ferrario CM,et al. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension, 1996,28:104-108
48. Tsllant EA, Diz DI, Ferrario CM. Antiproliferative actions of angiotension-(1-7) in vascular smooth muscle. Hypertension 1999;34(4 part 2):950-957.
49. Tallant EA,Diz DI,khosla MC,et al.ldentification and regulation of angiotensin II receptor subtypes on NG108-15 cells. Hypertension, 1991,17:1135-114450. Deddish PA, Marcis B, Jackman HC, et al.N-domain-specific substrate and c-domain inhibitors of angiotensin-covertingenzyme angiotensin-(1-7) and keto-ACE. Hypertension, 1998,31:912-917
51. Minshall RD,Tan F,Nakamura F,et al.Potentiation of the actions of bradykinin by angiotensinlcoverting enzyme(ACE) inbitors:the role of expressed and ACE in CHO cells. Circ Res,1997,81:848-856
52. Minshall RD,Erdos EG,Vogel SM.Angiotensinl coverting enzyme inhibitors potentiate brdykinin's inortropic effects independentlly of blocking its inactivation. Am J Cardiol,1997,80:132-136
53. Iyber SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension. 1998;31 [part2]:356- 361
54. Zyer SN, Chappel MC, Avevill DB, et al. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension. 1998;31:699-705.
55. Kohara K, Brosnihan KB, Ferrario CM, Angiotensin-(1-7) in spontaneously hypertensive rat. Peptides.1993;14:883-891
56. Chappell MC, Pirro NT, Sykes A. et al. Metabolism of angiotensin-(1-7) by angiotensin-coverting enzyme .Hypertension. 1998;31[part2]:362-367.
57. Tallant EA, Ferrario CM. Biology of angiotensin II receptor inhabition with a focus on losartan.a new drug for treatment of hypertension. Exp Opin Invest Drugs 1996;5:1201-1214
58. Ferrario CM, Martell N,Pinillas C,et al.Essential hypertension in associated with low urinary levels of angiotensin-(1-7).??Hypertension, 1996,28:515
59. Chappell MC,Diz DI,Ferrario CM.Urinary angiotensin-(1- 7):influence of converting enzyme and neprilysin inhibition. Hypertension, 1995,26:542
60. Ferrario CM, Chappell MC, Tallant EA, et al. Counterregulatory Actions of angiotensin-(1-7). Hypertension, 1997;30(part 2):535-5411 Swedberg K, Held P, Kjekshus J, et al. Effects of the earl administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study Ⅱ (CONSENSUS Ⅱ). N Engl J Med, 1992, 327: 678-684.
2 Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet, 1994, 343: 1115-1122.
3 ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet, 1995, 345: 669-685.
4 Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction (CCS-1). Lancet, 1995, 345: 686-687.
5 Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventrieular enlargement trial. N Engl J Med, 1992, 327:??669-677.
6 Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. N Engl J Med, 1995, 332: 80-85.
7 The Acute Infarction Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet, 1993, 342:821-828.
8 Hall AS, Murray GD, Ball SG. Follow up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet, 1997, 349:1493- 1497.
9 ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Circulation, 1998, 97:2202-2212.
10 MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease, part I: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet, 1990, 335: 765-774.
11 Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensinconverting enzyme inhibitors in cardiac and vascular protection. Circulation, 1994, 90:2056-2069.
12 Iwai N, Kinoshita, Ohmichi N, et al. Renin is expressed in rat macrophage/monocyte cells. Hypertension, 1996, 27(3 Pt 1): 399-403.
13 Danser AHJ, van Kesteren CAM, Bax WA, et al.??Prorenin,renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation, 1997, 96:220-226.
14 de Lannoy LM, Schalekamp MA, Saxena PR, et al. Localization and production of angiotensin II in the isolated perfused rat heart. Hypertension, 1998, 31:1111-1117.
15 Lindpainter K, Niedermaier N, Drexler H, et al. Left ventricular remodelling after myocardial infarction. J Cardiovasc Pharmacol, 1992, 20 (Suppl 1): S41-47.
16 Zhuo JL, Froomes P, Casley D, et al. Perindopril chronically inhibits angiotensin converting enzyme in both the endothelium and adventitial of the internal mammay artery in patients with ischemic heart disease. Circulation. 1997, 96: 174-182.
17 Hilgers KF, Veelken R, Schmieder RE, et al. Angiotensinases restrict locally generated angiotensin II to the blood vessel wall. Hypertension. 1998, 31(1 Pt 2): 368-372.
18 Naftilin AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest. 1989, 83:1419-1474.
19 Naftilin AJ, Pratt RE,Eldbridge CS, et al. Angiotensin II induces c-fos expression in smooth muscle cell via transcriptional control. Hypertension; 1989, 13: 706-711.
20 Morishita R, Gibbons GH, Dllison KE, et al. Evidence for direct local effect of angiotensin in vascular hypertrophy: in vivo gene transfer of angiotensin converting enzyme. J Clin Invest. 1994, 94: 978-984.
21 Isner JM, Kearney M, Bortman S,et al.Apoptosis in human atherosclerosis and restenosis. Circulation. 1995, 91: 2703- 2711.22 Gohlke P, Lamberty V, Kuwer I, et al. Long-term low-dose angiotensin converting enzyme inhibitor treatment increases vascular cyclic guanosine 3',5'--monophosphate. Hypertension. 1993, 22:682-687.
23 Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 1997, 95: 1115-1118.
24 Gallagher AM, Yu H, Printz MR Bradykinin-induced reduction in collagen gene expression involve prostacyclin. Hypertension, 1998, 32:84-88.
25 Huang W, Gelas FA, Osborne-Pellegrin MJ. Protection of the arterial internal elastic lamina by inhibition of the reninangiotensin system in the rat. Circ Res, 1998, 82: 879-890.
26 Mancini GB, Henry GC, Macaya C, et al. Angiotensinconverting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfuction) Study.Circulation, 1996, 94: 258-265.
27 Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide antiotensin IV. J Clin Invest, 1995, 96: 2515-2520.
28 Vaughan DE, Pfeffer MA, Menapace FJ, et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation, 1997, 96: 442-447.
29 Gibbons GH. Vasculoprotective and cardioprotective mechanism of angiotensin-converting enzyme inhibition: the homeostatic balanc between angiotensin II and nitric oxide. Clin Cardiol, 1997, 20(Suppl II) 1118-1125.
30 Hu K, Gaudron P, Anders HJ, et al. Chronic effects of early??started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin. Cardiovasc Res, 1998, 39: 401-412.
31 Makino N, Sugano M, Hata T, et al. Chronic low-dose treatment with enalapril induced cardiac regression of left ventricular hypertrophy. Mol Cell Biochem, 1996, 163-164.
32 Urata H, Ganten D, Dishiumura H. Chymase-dependent angiotensin Ⅱ forming system in humans. Am J Hypertens, 1996, 9: 277-84.